Smoking cessation may deteriorate glycemic control in diabetic patients
the ONA take:
Patients with type 2 diabetes mellitus who quit smoking see a temporary deterioration in glycemic control that may last up to three years, according to a recent study published in The Lancet Diabetes & Endocrinology.
Researchers led by Deborah Lycett, PhD, of Convetry University studied primary care records of 10,692 adult smokers with type 2 diabetes mellitus over six years to see if there was any association between diabetes control and smoking cessation.
They found that in 3,131 people (29 percent) who had quit for at least one year, HbA1c increased by 2.3 mmol/mol before gradually decreasing as abstinence continued.
During the same amount of time, 5,831 (55 percent) of patients who continually smoked experienced a more gradual increase in HbA1c. Those who quit saw comparable HbA1c levels with continual smokers after three years of quitting.
“Knowing that deterioration in blood glucose control occurs around the time of stopping smoking helps to prepare those with diabetes and their clinicians to be proactive in tightening their glycemic control during this time,” Dr. Lycett concluded.
Patients with type 2 diabetes mellitus who quit smoking see a temporary deterioration in glycemic control that may last up to three years.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|